Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xoma

Executive Summary

Company's plan to request that the San Francisco Federal Court award 40% of royalties from future U.S. sales of Centocor's Centoxin (HA-1A) antisepsis monoclonal antibody is noted in Centocor's Jan. 21 Tocor II prospectus. Xoma has not issued any press releases or public statements outlining the request, which grows out of an Oct. 28 jury decision that Centoxin infringes Xoma's patent for its E5 monoclonal antibody-based anti-endotoxin product ("The Pink Sheet" Feb 24, p. 7).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS020504

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel